title: Systems biology and p4 medicine: past, present, and future.
abstract: Studying complex biological systems in a holistic rather than a "one gene or one protein" at a time approach requires the concerted effort of scientists from a wide variety of disciplines. The Institute for Systems Biology (ISB) has seamlessly integrated these disparate fields to create a cross-disciplinary platform and culture in which "biology drives technology drives computation." To achieve this platform/culture, it has been necessary for cross-disciplinary ISB scientists to learn one another's languages and work together effectively in teams. The focus of this "systems" approach on disease has led to a discipline denoted systems medicine. The advent of technological breakthroughs in the fields of genomics, proteomics, and, indeed, the other "omics" is catalyzing striking advances in systems medicine that have and are transforming diagnostic and therapeutic strategies. Systems medicine has united genomics and genetics through family genomics to more readily identify disease genes. It has made blood a window into health and disease. It is leading to the stratification of diseases (division into discrete subtypes) for proper impedance match against drugs and the stratification of patients into subgroups that respond to environmental challenges in a similar manner (e.g. response to drugs, response to toxins, etc.). The convergence of patient-activated social networks, big data and their analytics, and systems medicine has led to a P4 medicine that is predictive, preventive, personalized, and participatory. Medicine will focus on each individual. It will become proactive in nature. It will increasingly focus on wellness rather than disease. For example, in 10 years each patient will be surrounded by a virtual cloud of billions of data points, and we will have the tools to reduce this enormous data dimensionality into simple hypotheses about how to optimize wellness and avoid disease for each individual. P4 medicine will be able to detect and treat perturbations in healthy individuals long before disease symptoms appear, thus optimizing the wellness of individuals and avoiding disease. P4 medicine will 1) improve health care, 2) reduce the cost of health care, and 3) stimulate innovation and new company creation. Health care is not the only subject that can benefit from such integrative, cross-disciplinary, and systems-driven platforms and cultures. Many other challenges plaguing our planet, such as energy, environment, nutrition, and agriculture can be transformed by using such an integrated and systems-driven approach.
authors.affiliation: President, Institute for Systems Biology, Seattle, WA, USA.
authors.forename: Leroy
authors.initials: L
authors.lastname: Hood
keywords: P4 medicine; disease stratification; patient stratification; personalized medicine; systems biology; systems medicine; systems-driven diagnostics
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):419-24
references.pmid: 22203961
references.citation: Nat Med. 2011 Jul 31;17(8):1015-9
references.pmid: 21804541
references.citation: Mol Syst Biol. 2009;5:252
references.pmid: 19308092
references.citation: Genomics Proteomics Bioinformatics. 2012 Aug;10(4):181-5
references.pmid: 23084773
references.citation: Annu Rev Anal Chem (Palo Alto Calif). 2008;1:1-43
references.pmid: 20636073
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
references.pmid: 19246379
references.citation: FASEB J. 1987 Dec;1(6):502-5
references.pmid: 3479371
references.citation: Nat Med. 2011 Jun;17(6):738-43
references.pmid: 21602800
references.citation: Am J Hum Genet. 2011 Sep 9;89(3):382-97
references.pmid: 21855840
references.citation: Science. 2010 Apr 30;328(5978):636-9
references.pmid: 20220176
references.citation: Dis Markers. 2010;28(4):199-207
references.pmid: 20534905
references.citation: Lab Invest. 2011 Dec;91(12):1787-95
references.pmid: 21931299
references.citation: Recent Pat Biomed Eng. 2008;2008(1):60-67
references.pmid: 21709726
references.citation: J Proteome Res. 2013 May 3;12(5):2034-44
references.pmid: 23540550
references.citation: N Biotechnol. 2012 Sep 15;29(6):613-24
references.pmid: 22450380
references.citation: Bioinformatics. 2011 Feb 1;27(3):391-8
references.pmid: 21193522
references.citation: Proteomics. 2012 Sep;12(18):2773-83
references.pmid: 22807061
references.citation: Mol Cell Proteomics. 2011 Sep;10(9):M110.006353
references.pmid: 21632744
references.citation: Nano Lett. 2012 Dec 12;12(12):6101-6
references.pmid: 23130660
references.citation: J Intern Med. 2012 Feb;271(2):111-21
references.pmid: 22142401
references.citation: Brief Funct Genomic Proteomic. 2008 Jul;7(4):239-48
references.pmid: 18579616
references.citation: Nat Nanotechnol. 2012 Oct;7(10):623-9
references.pmid: 23042546
references.citation: Mol Cell Proteomics. 2013 Apr;12(4):1005-16
references.pmid: 23408683
references.citation: J Proteome Res. 2002 Sep-Oct;1(5):399-409
references.pmid: 12645911
references.citation: Nat Nanotechnol. 2009 Nov;4(11):698-9
references.pmid: 19898513
references.citation: Nat Methods. 2012 May 30;9(6):555-66
references.pmid: 22669653
references.citation: Angew Chem Int Ed Engl. 2011 Aug 1;50(32):7378-80
references.pmid: 21717543